KR20070029204A - 혈관신생-저해 키메릭 단백질 및 그 사용 - Google Patents
혈관신생-저해 키메릭 단백질 및 그 사용 Download PDFInfo
- Publication number
- KR20070029204A KR20070029204A KR1020067026641A KR20067026641A KR20070029204A KR 20070029204 A KR20070029204 A KR 20070029204A KR 1020067026641 A KR1020067026641 A KR 1020067026641A KR 20067026641 A KR20067026641 A KR 20067026641A KR 20070029204 A KR20070029204 A KR 20070029204A
- Authority
- KR
- South Korea
- Prior art keywords
- chimeric protein
- flt
- kdr
- kdrd3
- fltd2
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pregnancy & Childbirth (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
Description
Claims (13)
- VEGF 리셉터 FLT-1 및 KDR의 다른 단편들로 구성되는 키메릭 단백질의 형태로서, 하기 군에서 선택되어지는 것을 특징으로 하는 키메릭 단백질;a. KDR의 1차 Ig-유사 도메인, FLT-1의 2차 Ig-유사 도메인 및 KDR의 3차 Ig-유사 도메인으로 구성되고, KDRd1-FLTd2-KDRd3로 표기;b. FLT-1의 2차 Ig-유사 도메인 및 KDR의 3차 및 4차 Ig-유사 도메인으로 구성되고, FLTd2-KDRd3,4로 표기;c. FLT-1의 2차 Ig-유사 도메인, KDR의 3차 Ig-유사 도메인 및 FLT-1의 4차 Ig-유사 도메인으로 구성되고, FLTd2-KDRd3-FLTd4로 표기;d. FLT-1의 2차 Ig-유사 도메인, KDR의 3차, 4차 및 5차 Ig-유사 도메인으로 구성되고, FLTd2-KDRd3,4,5로 표기;e. FLT-1의 2차 Ig-유사 도메인, KDR의 3차 Ig-유사 도메인 및 FLT-1의 4차 및 5차 Ig-유사 도메인으로 구성되고, FLTd2-KDRd3-FLTd4,5로 표기.
- 청구항 1의 키메릭 단백질과 다음의 그룹에서 선택된 인간 이뮤노글로불린 Fc로 구성되는 것을 특징으로 하는 키메릭 단백질:KDRd1-FLTd2-KDRd3-Fc로 표기되는 FP2';FLTd2-KDRd3,4-Fc로 표기되는 FP3';FLTd2-KDRd3-FLTd4-Fc로 표기되는 FP4';FLTd2-KDRd3,4,5-Fc로 표기되는 FP5';FLTd2-KDRd3-FLTd4,5-Fc로 표기되는 FP6'.
- 제 2항에 있어서, 인간 이뮤노글로불린의 클래스 또는 서브 클래스로부터 유래된 이뮤노글로불린 Fc를 특징으로 하는 키메릭 단백질.
- 제 3항에 있어서, 이뮤노글로불린 Fc 단편이 전장 Fc이거나 또는 Fc 시퀀스의 단편인 것을 특징으로 하는 키메릭 단백질.
- 제 2항에 있어서, FP3는 아미노산 시퀀스가 SEQ ID NO. 7로 나타내어지는 것을 특징으로 하는 키메릭 단백질.
- 청구항 1~4에서 선택된 어느 하나의 키메릭 단백질을 인코딩하는 재조합 DNA.
- 제 5항에 있어서, DNA 시퀀스가 SEQ ID NO. 6으로 나타내어지는 것을 특징으로 하는 키메릭 단백질을 인코딩하는 재조합 DNA.
- 제 6항 또는 제7항의 재조합 DNA 시퀀스를 포함하는 벡터로서, 상기 벡터가 플라스미드, 바이러스, 또는 DNA 절편인 벡터
- 제 8항의 재조합 벡터를 포함하는 재조합 숙주로서, 상기 숙주세포가 진핵 세포이거나 또는 원핵 세포인 재조합 숙주.
- 항-혈관신생 약물의 제조에 있어서의 청구항 1-5 중 어느 하나에 따른 키메릭 단백질의 용도.
- 청구항 1-5 중 어느 하나에 따른 키메릭 단백질 및 약리학적으로 허용되는 담체를 포함하는 약리학적 조성물.
- 제 11항에 있어서, 상기 약리학적 조성물은 주사 용액인 약리학적 조성물.
- 종양, 당뇨병성 망막병증, 관절염, 빈혈, 자궁내막 증식증을 포함하는 혈관신생-관련 질병 치료에서의 청구항 11에 따른 약리학적 조성물의 용도.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200410044965.7 | 2004-06-08 | ||
CN200410044965 | 2004-06-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070029204A true KR20070029204A (ko) | 2007-03-13 |
KR100897379B1 KR100897379B1 (ko) | 2009-05-14 |
Family
ID=35503012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067026641A KR100897379B1 (ko) | 2004-06-08 | 2005-06-08 | 혈관신생-저해 키메릭 단백질 및 그 사용 |
Country Status (13)
Country | Link |
---|---|
US (2) | US7750138B2 (ko) |
EP (1) | EP1767546B1 (ko) |
JP (1) | JP4680997B2 (ko) |
KR (1) | KR100897379B1 (ko) |
AT (1) | ATE548384T1 (ko) |
BR (1) | BRPI0512286B8 (ko) |
CA (1) | CA2569108C (ko) |
DK (1) | DK1767546T3 (ko) |
ES (1) | ES2381014T3 (ko) |
PL (1) | PL1767546T3 (ko) |
PT (1) | PT1767546E (ko) |
RU (1) | RU2355414C2 (ko) |
WO (1) | WO2005121176A1 (ko) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060217311A1 (en) | 2005-03-25 | 2006-09-28 | Daniel Dix | VEGF antagonist formulations |
US8216575B2 (en) * | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
CN100502945C (zh) * | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在治疗眼睛疾病中的应用 |
CA2654510C (en) | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
CN101838329A (zh) | 2009-03-18 | 2010-09-22 | 嘉和生物药业有限公司 | 抗血管新生融合蛋白 |
KR101248912B1 (ko) * | 2009-12-31 | 2013-03-29 | 한양대학교 산학협력단 | 항혈관신생 활성을 가지는 재조합 아데노바이러스 |
SG191334A1 (en) | 2011-01-13 | 2013-08-30 | Regeneron Pharma | Use of a vegf antagonist to treat angiogenic eye disorders |
MA42648B1 (fr) | 2012-06-01 | 2019-10-31 | Novartis Ag | Seringue |
JOP20200175A1 (ar) | 2012-07-03 | 2017-06-16 | Novartis Ag | حقنة |
AU2012101678B4 (en) | 2012-07-03 | 2013-01-24 | Novartis Ag | Use of device |
AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
WO2014203182A1 (en) | 2013-06-20 | 2014-12-24 | Novartis Ag | Use of a vegf antagonist in treating choroidal neovascularisation |
JP2016522248A (ja) | 2013-06-20 | 2016-07-28 | ノバルティス アーゲー | ポリープ状脈絡膜血管症の治療 |
EP3010526A1 (en) | 2013-06-20 | 2016-04-27 | Novartis AG | Use of a vegf antagonist in treating macular edema |
MX2016000384A (es) | 2013-07-11 | 2016-04-29 | Novartis Ag | Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos. |
KR20230152151A (ko) | 2013-07-12 | 2023-11-02 | 이베릭 바이오, 인크. | 안과적 질환을 치료하거나 예방하기 위한 방법 |
RU2634406C1 (ru) * | 2014-01-25 | 2017-10-26 | Чэнду Канхун Байотекнолоджиз Ко., Лтд. | Слитый белок, ингибирующий ангиогенез или рост сосудов, и его применение |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
CA2987884C (en) | 2015-06-28 | 2023-01-03 | Allgenesis Biotherapeutics Inc. | Fusion peptides comprising disintegrin binding to integrin .alpha.v.beta.x or .alpha.5.beta.1 and their use in treating an angiogenic disease |
TW202340452A (zh) | 2015-08-04 | 2023-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
CN109073660B (zh) | 2016-02-29 | 2022-10-28 | 麦恩泰科特有限公司 | 可用于治疗湿性年龄相关性黄斑变性的预测性标志物 |
EP3634543B1 (en) | 2017-06-08 | 2024-06-05 | Novartis AG | Injection device and injection solution transferring system |
TW201904610A (zh) | 2017-06-14 | 2019-02-01 | 德商拜耳製藥公司 | 用於治療新生血管型青光眼之非抗體vegf拮抗劑 |
AU2018290633B9 (en) * | 2017-06-30 | 2021-04-01 | Korea Advanced Institute Of Science And Technology | Conjugate of VEGF-Grab protein and drug, and use thereof |
MX2020000228A (es) | 2017-07-06 | 2020-08-10 | Regeneron Pharma | Proceso de cultivo celular para producir una glicoproteina. |
JOP20200275A1 (ar) | 2018-05-10 | 2020-11-02 | Regeneron Pharma | صيغ تحتوي على بروتين اندماج لمستقبلvegf مرتفعة التركيز |
US20220332792A1 (en) * | 2019-09-04 | 2022-10-20 | University Of Massachusetts | Adeno-associated virus vector platform for delivery of kh902 (conbercept) and uses thereof |
JP2022553640A (ja) | 2019-10-10 | 2022-12-26 | コディアック サイエンシーズ インコーポレイテッド | 眼障害を処置する方法 |
WO2021108530A1 (en) * | 2019-11-26 | 2021-06-03 | University Of Massachusetts | Recombinant adeno-associated virus for delivery of kh902 (conbercept) and uses thereof |
WO2021119544A1 (en) | 2019-12-12 | 2021-06-17 | Novartis Ag | Injection device and injection solution transferring system |
WO2022013787A1 (en) | 2020-07-16 | 2022-01-20 | Novartis Ag | Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules |
CA3192736A1 (en) * | 2020-09-03 | 2022-03-10 | University Of Massachusetts | Adeno-associated virus for delivery of kh902 (conbercept) and uses thereof |
PE20240922A1 (es) | 2021-05-17 | 2024-04-30 | Regeneron Pharma | Regimenes de antagonistas del vegf en dosis alta extendidos para el tratamiento de trastornos oculares angiogenicos |
EP4145456A1 (en) | 2021-09-06 | 2023-03-08 | Bayer AG | Prediction of a change related to a macular fluid |
US20240024420A1 (en) | 2022-03-15 | 2024-01-25 | Regeneron Pharmaceuticals, Inc. | Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders |
JP2023135645A (ja) | 2022-03-15 | 2023-09-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 血管新生性眼障害の処置のための長期高用量vegfアンタゴニストレジメン |
US11723955B1 (en) | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0694042T3 (da) * | 1993-03-25 | 2005-02-14 | Merck & Co Inc | Inhibitor af vaskulær endothelcellevækstfaktor |
US6020473A (en) * | 1995-08-25 | 2000-02-01 | Genentech, Inc. | Nucleic acids encoding variants of vascular endothelial cell growth factor |
US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
US6833349B2 (en) * | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
NZ515913A (en) * | 1999-06-08 | 2004-01-30 | Regeneron Pharma | Modified chimeric polypeptides with improved pharmacokinetic properties |
WO2005046602A2 (en) * | 2003-11-10 | 2005-05-26 | Greenville Hospital System | Vegf receptor antagonists |
CN101134777A (zh) * | 2006-08-31 | 2008-03-05 | 苏州思坦维生物技术有限责任公司 | 可拮抗血管内皮细胞生长因子的人源化的免疫球蛋白的制备方法及其组合应用 |
-
2005
- 2005-06-08 WO PCT/CN2005/000802 patent/WO2005121176A1/zh active Application Filing
- 2005-06-08 RU RU2006146995/15A patent/RU2355414C2/ru active
- 2005-06-08 EP EP05752254A patent/EP1767546B1/en active Active
- 2005-06-08 PT PT05752254T patent/PT1767546E/pt unknown
- 2005-06-08 PL PL05752254T patent/PL1767546T3/pl unknown
- 2005-06-08 AT AT05752254T patent/ATE548384T1/de active
- 2005-06-08 US US11/628,735 patent/US7750138B2/en active Active
- 2005-06-08 BR BRPI0512286A patent/BRPI0512286B8/pt active IP Right Grant
- 2005-06-08 ES ES05752254T patent/ES2381014T3/es active Active
- 2005-06-08 JP JP2007526176A patent/JP4680997B2/ja active Active
- 2005-06-08 CA CA2569108A patent/CA2569108C/en active Active
- 2005-06-08 KR KR1020067026641A patent/KR100897379B1/ko active IP Right Grant
- 2005-06-08 DK DK05752254.2T patent/DK1767546T3/da active
-
2010
- 2010-05-04 US US12/773,315 patent/US20100215655A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2008503243A (ja) | 2008-02-07 |
DK1767546T3 (da) | 2012-04-23 |
CA2569108C (en) | 2012-08-21 |
ES2381014T3 (es) | 2012-05-22 |
US20080206238A1 (en) | 2008-08-28 |
US7750138B2 (en) | 2010-07-06 |
EP1767546A1 (en) | 2007-03-28 |
CA2569108A1 (en) | 2005-12-22 |
RU2006146995A (ru) | 2008-07-20 |
BRPI0512286B8 (pt) | 2021-05-25 |
PL1767546T3 (pl) | 2012-07-31 |
JP4680997B2 (ja) | 2011-05-11 |
WO2005121176A1 (fr) | 2005-12-22 |
ATE548384T1 (de) | 2012-03-15 |
KR100897379B1 (ko) | 2009-05-14 |
EP1767546A4 (en) | 2008-03-19 |
PT1767546E (pt) | 2012-03-20 |
BRPI0512286A (pt) | 2008-03-18 |
BRPI0512286B1 (pt) | 2020-03-24 |
US20100215655A1 (en) | 2010-08-26 |
RU2355414C2 (ru) | 2009-05-20 |
EP1767546B1 (en) | 2012-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100897379B1 (ko) | 혈관신생-저해 키메릭 단백질 및 그 사용 | |
KR100759295B1 (ko) | April 수용체(bcma) 및 그 용도 | |
KR101204229B1 (ko) | 최적화된 TACI-Fc 융합 단백질 | |
CN100447244C (zh) | Baff受体(bcma),一种免疫调节剂 | |
KR100888022B1 (ko) | 면역글로불린 Fc와 인간 아포리포단백질(a)크링글절편의 융합단백질 LK8Fc | |
JP2009539412A (ja) | 汎細胞表面レセプター特異的な治療薬 | |
CN1304427C (zh) | 抑制血管新生的融合蛋白质及其用途 | |
US20020147326A1 (en) | Hexameric fusion proteins and uses therefor | |
KR20150030706A (ko) | 이중 수용체 길항 항원-결합 단백질 및 그것의 사용 | |
CN112661858A (zh) | 重组人生长激素Fc融合蛋白和用途及其工程细胞株 | |
CN111690070A (zh) | 一种sPD-1-Fc-sTGFβRII融合蛋白及其应用 | |
KR20140093942A (ko) | 인간 노치1 디코이 | |
CN107223131A (zh) | 经修饰的dkk2蛋白、对其编码的核酸、其制备方法及其用途 | |
KR20220151176A (ko) | 혈중 콜레스테롤 저하용, 심혈관 대사질환의 예방 또는 치료용 및 항염용 약학적 조성물 | |
CN101514232B (zh) | 一种RANKL-Fc融合蛋白及其制备方法和用途 | |
CN108250290B (zh) | Ccr4的n端重组蛋白及其用途 | |
KR101572912B1 (ko) | 돼지 cd7 유전자 및 이를 이용한 cd7 융합 이뮤노글로불린 | |
CN108409861A (zh) | 一种双特异性抗体及其应用 | |
CN116209473A (zh) | 用于癌症疾病免疫治疗的cxcl9及其变体 | |
CN108484772A (zh) | 抗her2抗原的人源化抗体h5l5及其应用 | |
RU2787060C1 (ru) | НУКЛЕОТИДНАЯ ПОСЛЕДОВАТЕЛЬНОСТЬ, КОДИРУЮЩАЯ СЛИТЫЙ БЕЛОК, СОСТОЯЩИЙ ИЗ РАСТВОРИМОГО ВНЕКЛЕТОЧНОГО ФРАГМЕНТА ЧЕЛОВЕЧЕСКОГО Dll4 И КОНСТАНТНОЙ ЧАСТИ ТЯЖЕЛОЙ ЦЕПИ ЧЕЛОВЕЧЕСКОГО IgG4 | |
CN102030828A (zh) | 一种高亲和力的CTLA4-Ig融合蛋白突变体 | |
CN112794906B (zh) | 抗4-1bb的单链抗体及其应用 | |
CN108355141B (zh) | 一种基于TIM-4-Fc融合蛋白的治疗变应性疾病的药物及其制备方法 | |
CN101371923B (zh) | Baff受体(bcma),一种免疫调节剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
E902 | Notification of reason for refusal | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130502 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20140507 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20150430 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20160425 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20170413 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20190508 Year of fee payment: 11 |